GT Biopharma
GTBP
59 hedge funds and large institutions have $1.03M invested in GT Biopharma in 2026 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 5 closing their positions.
340% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 5
57% more capital invested
Capital invested by funds: $657K → $1.03M (+$377K)
40% more funds holding
Funds holding: 42 → 59 (+17)
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
0.77% more ownership
Funds ownership: 5.11% → 5.88% (+0.77%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$43.5K |
| 2 |
EFG
Everhart Financial Group
Dublin,
Ohio
|
+$40.6K |
| 3 |
OWA
Opal Wealth Advisors
Jericho,
New York
|
+$33.2K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$30.6K |
| 5 |
4WM
49 Wealth Management
Austin,
Texas
|
+$26K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
-$30.6K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$27K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$18.6K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$11.2K |
| 5 |
I
INVST
Indianapolis,
Indiana
|
-$9.55K |
GTBP Hedge Fund Activity: Q2 2026 in Review
59 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q2 2026, worth a combined $1.03M — up 57% from $657K a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new GTBP positions and 5 closed out — a net gain of 17 holders — while 9 added to existing stakes and 8 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $43.5K. The largest seller was Vanguard Capital Management, cutting an estimated $30.6K.
- 59 institutional investors held GT Biopharma (GTBP) as of Q2 2026, up from 42 in Q1 2026.
- Funds reported $1.03M of GT Biopharma stock for Q2 2026, up 57% quarter-over-quarter.
- 22 funds opened new GT Biopharma positions in Q2 2026 and 5 closed out, a net change of +17 holders.
- The largest GT Biopharma buyer in Q2 2026 was HRT Financial, an estimated $43.5K added.
- The largest GT Biopharma seller in Q2 2026 was Vanguard Capital Management, an estimated $30.6K sold.
Based on aggregated 13F filings for Q2 2026.